Collaboration with Pfizer will enable Atavistik Bio to extend the reach of its platform to potentially address a broader range of oncology indications, while simultaneously progressing its ...
Collaboration will leverage Atavistik Bio’s proprietary AMPS™ platform to rapidly identify and validate novel allosteric binders against two undisclosed, Pfizer-designated targets Atavistik ...
Collaboration will leverage Atavistik Bio's proprietary AMPSTM platform to rapidly identify and validate novel allosteric binders against two undisclosed, Pfizer-designated targets Atavistik Bio ...
The pharma giant is teaming up with Atavistik Bio, leveraging the smaller company's cutting-edge AMPS platform to develop groundbreaking precision allosteric therapeutics. The focus? Tackling two ...
Collaboration will leverage Atavistik Bio's proprietary AMPS™ platform to rapidly identify and validate novel allosteric binders against two undisclosed, Pfizer-designated targets Atavistik Bio has ...
Atavistik Bio enters research collaboration with Pfizer to accelerate discovery of novel precision allosteric therapeutics: Cambridge, Massachusetts Friday, January 3, 2025, 15:00 ...
Atavistik Bio, Pfizer Collaborate To Accelerate Discovery Of Novel Precision Allosteric Therapeutics
(RTTNews) - Biotechnology company Atavistik Bio announced Thursday that it has entered into a research collaboration with Pfizer, Inc. (PFE) to accelerate the discovery of novel precision ...
Pfizer (NYSE:PFE) just made a bold move that could reshape the biotech landscape. The pharma giant is teaming up with Atavistik Bio, leveraging the smaller company's cutting-edge AMPS platform to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback